Number of the records: 1
FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF.
- 1.
SYSNO ASEP 0579894 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF. Author(s) Beneš, J. (CZ)
Kroupová, K. (CZ)
Kotrc, M. (CZ)
Petrák, J. (CZ)
Jarolim, P. (US)
Novosadová, Vendula (UMG-J)
Kautzner, J. (CZ)
Melenovský, V. (CZ)Number of authors 8 Article number 16004 Source Title Scientific Reports. - : Nature Publishing Group - ISSN 2045-2322
Roč. 13, č. 1 (2023)Number of pages 9 s. Language eng - English Country US - United States Keywords biomarker ; RV dysfunction ; cardiovascular medicine OECD category Biochemistry and molecular biology R&D Projects LX22NPO5102 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) Method of publishing Open access Institutional support UMG-J - RVO:68378050 UT WOS 001116558400022 EID SCOPUS 85172334413 DOI 10.1038/s41598-023-42558-4 Annotation There is no biomarker reflecting right ventricular dysfunction in HFrEF patients used in clinical practice. We have aimed to look for a circulating marker of RV dysfunction employing a quantitative proteomic strategy. The Olink Proteomics Multiplex panels (Cardiovascular Disease II, III, Cardiometabolic, and Inflammation Target Panels) identified FGF-23 to be the most differentially abundant (more than 2.5-fold) in blood plasma of HF patients with severe RV dysfunction (n=30) compared to those with preserved RV function (n=31). A subsequent ELISA-based confirmatory analysis of circulating FGF-23 in a large cohort of patients (n=344, 72.7% NYHA III/IV, LVEF 22.5%, 54.1% with moderate/severe RV dysfunction), followed by multivariable regression analysis, revealed that the plasma FGF-23 level was most significantly associated with RV dysfunction grade (p=0.0004) and congestion in the systemic circulation (p=0.03), but not with LV-ejection fraction (p=0.69) or estimated glomerular filtration rate (eGFR, p=0.08). FGF-23 was associated with the degree of RV dysfunction in both sub-cohorts (i.e. in patients with and without congestion, p<0.0001). The association between FGF-23 and RV-dysfunction remained significant after the adjustment for BNP (p=0.01). In contrast, when adjusted for BNP, FGF-23 was no longer associated with LV dysfunction (p=0.59). The Cox proportional hazard model revealed that circulating FGF-23 was significantly associated with adverse outcomes even after adjusting for BNP, LVEF, RV dysfunction grade and eGFR. Circulating FGF-23 isthus a biomarker of right ventricular dysfunction in HFrEF patients regardless of congestion status. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2024 Electronic address https://www.nature.com/articles/s41598-023-42558-4
Number of the records: 1